NO331030B1 - Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase - Google Patents

Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase

Info

Publication number
NO331030B1
NO331030B1 NO20045267A NO20045267A NO331030B1 NO 331030 B1 NO331030 B1 NO 331030B1 NO 20045267 A NO20045267 A NO 20045267A NO 20045267 A NO20045267 A NO 20045267A NO 331030 B1 NO331030 B1 NO 331030B1
Authority
NO
Norway
Prior art keywords
reverse transcriptase
inhibitory activity
activity against
nucleoside reverse
pyrimidine compounds
Prior art date
Application number
NO20045267A
Other languages
English (en)
Norwegian (no)
Other versions
NO20045267L (no
Inventor
Marie-Pierre T M M G De Bethune
Paul Stoffels
Jens Marcel Van Roey
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20045267L publication Critical patent/NO20045267L/no
Publication of NO331030B1 publication Critical patent/NO331030B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
NO20045267A 2002-05-13 2004-12-01 Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase NO331030B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076897 2002-05-13
PCT/EP2003/050158 WO2003094920A1 (en) 2002-05-13 2003-05-13 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission

Publications (2)

Publication Number Publication Date
NO20045267L NO20045267L (no) 2005-02-14
NO331030B1 true NO331030B1 (no) 2011-09-19

Family

ID=29414777

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20045267A NO331030B1 (no) 2002-05-13 2004-12-01 Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase
NO20110298A NO334067B1 (no) 2002-05-13 2011-02-22 Anvendelse av triazinforbindelser for fremstilling av legemidler til forebygging av seksuell overføring av HIV

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20110298A NO334067B1 (no) 2002-05-13 2011-02-22 Anvendelse av triazinforbindelser for fremstilling av legemidler til forebygging av seksuell overføring av HIV

Country Status (27)

Country Link
US (4) US7935710B2 (zh)
EP (1) EP1505980B1 (zh)
JP (2) JP4530848B2 (zh)
KR (1) KR101095358B1 (zh)
CN (2) CN1668305B (zh)
AP (1) AP2024A (zh)
AR (1) AR039540A1 (zh)
AT (1) ATE376420T1 (zh)
AU (1) AU2003240844B2 (zh)
BR (2) BRPI0310021B8 (zh)
CA (1) CA2486078C (zh)
CY (1) CY1110249T1 (zh)
DE (1) DE60317060T2 (zh)
DK (1) DK1505980T3 (zh)
EA (1) EA011298B1 (zh)
ES (1) ES2294291T3 (zh)
HK (1) HK1173141A1 (zh)
HR (1) HRP20041177B1 (zh)
IL (1) IL165174A (zh)
MX (1) MXPA04011392A (zh)
NO (2) NO331030B1 (zh)
NZ (1) NZ536976A (zh)
PL (1) PL215128B1 (zh)
PT (1) PT1505980E (zh)
SI (1) SI1505980T1 (zh)
WO (1) WO2003094920A1 (zh)
ZA (1) ZA200409984B (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
CN102151270A (zh) 2003-02-07 2011-08-17 詹森药业有限公司 预防hiv感染的嘧啶衍生物
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
BRPI0607811B8 (pt) * 2005-02-18 2021-05-25 Janssen R & D Ireland derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007071199A1 (fr) * 2005-12-22 2007-06-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Composes de 2,4-disubstituee amido-6-substituee-[1,3,5]triazine ou de 1,3-pyrimidine, leurs procedes d'elaboration, et preparations pharmaceutiques les contenant et leurs utilisations
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
RU2008152195A (ru) 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
AU2007257701A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
BRPI0722383A2 (pt) 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
ES2550152T3 (es) * 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
US9006243B2 (en) * 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines
ES2618057T3 (es) * 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2576541T3 (en) 2010-06-04 2016-05-30 Hoffmann La Roche Aminopyrimidine AS LRRK2 MODULATORS
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
LT3124483T (lt) 2010-11-10 2019-09-25 Genentech, Inc. Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US20130039959A1 (en) * 2011-04-19 2013-02-14 Brian Vincent Sokol Method of inhibiting hiv and barrier-forming composition therefor
CN103619341A (zh) 2011-04-19 2014-03-05 Arms制药有限公司 抑制有害微生物的方法及其阻隔形成组合物
MX360404B (es) 2011-05-04 2018-10-31 Ariad Pharma Inc Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN102675212B (zh) * 2012-05-09 2014-11-05 昆明理工大学 N-取代苯基-2-((1h-苯并咪唑-2-基)巯基)乙酰胺类衍生物及其用途
CA2891412A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
JP6466107B2 (ja) * 2014-09-04 2019-02-06 東ソー・ファインケム株式会社 ４−フェニルチオ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105085410B (zh) * 2015-08-21 2017-10-10 武汉工程大学 一种二芳基嘧啶类hiv‑1抑制剂及其制备方法
WO2017077520A1 (en) 2015-11-06 2017-05-11 Ineb - Instituto Nacional De Engenharia Biomédica A composition for use in a method for prevention or treatment of human immunodeficiency virus infections
CN106478521A (zh) * 2016-10-11 2017-03-08 武汉工程大学 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法
CN106866628A (zh) * 2017-02-27 2017-06-20 武汉工程大学 一种芳基杂芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途
MX2021003723A (es) * 2018-12-04 2021-05-13 Virox Tech Inc Composiciones antimicrobianas que contienen n-alquil gamma butirolactama de c3-c5 y usos de las mismas.
US20220033851A1 (en) * 2020-08-03 2022-02-03 Roger B. Swartz mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983393A (en) * 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
IT1229531B (it) 1988-01-20 1991-09-04 Univ Minnesota Composti nucleosidi dideossidideidrocarbociclici e formulazione farmaceutica che li contiene
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JPH075570B2 (ja) 1990-03-29 1995-01-25 三菱化学株式会社 ピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤
DK0539442T3 (da) 1990-07-19 1998-09-07 Wellcome Found Enzyminaktivatorer
GB9214720D0 (en) * 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
DE69414708T2 (de) * 1993-08-24 1999-04-15 Medivir Ab, Huddinge Verbindungen und methoden zur inhibition von hiv und verwandten viren
US6165493A (en) 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
DK0945443T3 (da) * 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV-hæmmende pyrimidinderivater
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
DE69929354T2 (de) * 1998-11-10 2006-09-14 Janssen Pharmaceutica N.V. 2,4-disubstierte triazinderivate mit anti-hiv aktivität
OA11674A (en) 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
PL351710A1 (en) * 1999-05-14 2003-06-02 Univ California Anti−inflammatory therapy for inflammatory mediated infection
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
ATE316781T1 (de) 1999-09-24 2006-02-15 Janssen Pharmaceutica Nv Antivirale feste dispersionen
US20030165540A1 (en) 2000-05-05 2003-09-04 Jen-Kuei Liu Sentinel virus II
US7034019B2 (en) * 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CA2439820A1 (en) * 2001-03-02 2002-09-12 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
US6951654B2 (en) 2001-03-27 2005-10-04 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina

Also Published As

Publication number Publication date
DE60317060D1 (de) 2007-12-06
SI1505980T1 (sl) 2008-02-29
CN102558070B (zh) 2016-01-13
JP4530848B2 (ja) 2010-08-25
CY1110249T1 (el) 2015-01-14
KR20050010798A (ko) 2005-01-28
NZ536976A (en) 2007-08-31
BR122014006936B1 (pt) 2020-11-24
CN1668305A (zh) 2005-09-14
BR122014006936B8 (pt) 2021-05-25
AR039540A1 (es) 2005-02-23
MXPA04011392A (es) 2005-02-17
IL165174A (en) 2011-01-31
AP2004003182A0 (en) 2004-12-31
EA200401494A1 (ru) 2005-06-30
EA011298B1 (ru) 2009-02-27
JP5256244B2 (ja) 2013-08-07
PL215128B1 (pl) 2013-10-31
ZA200409984B (en) 2006-07-26
AP2024A (en) 2009-08-11
BR0310021A (pt) 2005-02-15
PT1505980E (pt) 2008-01-17
NO334067B1 (no) 2013-12-02
NO20110298L (no) 2005-02-14
ATE376420T1 (de) 2007-11-15
BRPI0310021B8 (pt) 2021-05-25
JP2010189435A (ja) 2010-09-02
NO20045267L (no) 2005-02-14
BRPI0310021B1 (pt) 2018-03-13
CA2486078C (en) 2011-08-23
US7935710B2 (en) 2011-05-03
US20110165093A1 (en) 2011-07-07
AU2003240844B2 (en) 2008-09-11
US20170100399A1 (en) 2017-04-13
DE60317060T2 (de) 2008-07-24
US20200345733A1 (en) 2020-11-05
AU2003240844A1 (en) 2003-11-11
IL165174A0 (en) 2005-12-18
US20060166943A1 (en) 2006-07-27
ES2294291T3 (es) 2008-04-01
EP1505980A1 (en) 2005-02-16
KR101095358B1 (ko) 2011-12-16
HK1173141A1 (zh) 2013-05-10
CN1668305B (zh) 2013-06-12
WO2003094920A1 (en) 2003-11-20
HRP20041177A2 (hr) 2006-04-30
PL373840A1 (en) 2005-09-19
DK1505980T3 (da) 2008-02-11
CN102558070A (zh) 2012-07-11
CA2486078A1 (en) 2003-11-20
JP2005526846A (ja) 2005-09-08
HRP20041177B1 (hr) 2013-03-31
EP1505980B1 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
NO331030B1 (no) Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase
NO20045152L (no) Ikke-nukleosid-reverstranskriptaseinhibitorer
CY1110690T1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
MX2009005009A (es) Compuestos heterociclicos biciclicos 4-cianofenilamino sustituidos como inhibidores del virus de inmunodeficiencia humana.
MY169670A (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
NO20054264D0 (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
ZA200709481B (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
ATE410426T1 (de) Heterocyclische verbindungen alsccr5-antagonisten
WO2003002064A3 (en) Fused pyrimidine dhfr inhibitors as antibacterials
DK1246808T3 (da) 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
SE0100733D0 (sv) Non-nucleoside reverse transcriptase inhibitors
GT200300229A (es) Utilizacion de pirimetanilo en patogenos resistentes
BRPI0509562A (pt) uso de uma trioxopirimidina para o tratamento e a prevenção de doenças inflamatórias brÈnquicas
AR036546A1 (es) Composicion herbicida
TH85131A (th) สารประกอบฆ่าจุลินทรีย์ซึ่งมีไพริมิดีนหรือไทรอะซีน
EA200600522A1 (ru) Комбинации пиримидинсодержащего nnrti с ингибиторами обратной транскриптазы

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: JANSSEN SCIENCES IRELAND UC, IE

MK1K Patent expired